BCD38

Treatment of A549 cells with BCD38 (3-day treatment) induces transcriptomic changes, particularly the downregulation of cell cycle-related genes. These changes are similar to those resulting from DHX33 knockdown, but with weaker potency^[1].
Treatment with BCD38 significantly inhibits the anchorage-independent growth of human lung cancer cell lines A549 and H1299 in soft agar assays^[1].
Treatment with BCD38 significantly inhibits the migration of lung cancer cells A549 and H1299^[1].
BCD38 potently and selectively inhibits the helicase activity of wild-type recombinant DHX33 in vitro, with an IC₅₀ of 0.8 μM, while exerting only extremely weak inhibitory effects on other tested RNA helicases^[2].
BCD38 (10 μM) binds directly to recombinant DHX33 protein in vitro, with a K_d value of 4.7 μM^[2].
BCD38 (48 h) inhibits the viability of U251-MG cancer cells overexpressing DHX33 in vitro, with an IC₅₀ of 7.82 μM after 48 h of incubation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.